Allergan, Inc. v Galderma Research & Development

Link copied
Case Copied 26 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Allergan, Inc. v Galderma Research & Development [2015] APO 87

Patent Application:                2010252935

Title:Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection

Patent Applicant:                   Galderma Research & Development

Opponent:  Allergan, Inc.

Delegate:  Dr M-A. Fam

Decision Date:  15 December 2015

Hearing Date:  23 November 2015, in Canberra

Catchwords:  PATENTS – section 59 – opposition to the grant of a patent – grounds of novelty, inventive step, manner of manufacture, utility, fair basis and clarity considered – novelty – citation does not disclose all the features of the claims – inventive step – evidence does not establish that it would be a matter of routine to prepare an injectable composition comprising three active ingredients – claims define a manner of manufacture – claimed invention is useful – claims are fairly based and clear – opposition fails

Representation:  Patent applicant: Bernadette Hawkins of Cullens

Opponent: Christian Dimitriadis SC and Gavin Recchia of Davies Collison Cave

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2010252935

Title:Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection

Patent Applicant:                   Galderma Research & Development

Date of Decision:                   15 December 2015

DECISION

The opposition fails on all grounds.  Subject to appeal, I direct the application proceed to grant.  Costs according to Schedule 8 are awarded against Allergan, Inc.

REASONS FOR DECISION

Background

  1. The present application was filed by Galderma Research & Development (Galderma) and Symatese on 28 May 2010.  Symatese subsequently assigned its rights in the application to Galderma.  The application claimed priority from US 61/213322 having a filing date of 29 May 2009.  Following examination, the application was advertised accepted on 9 January 2014.  Galderma subsequently filed section 104 amendments on 2 January 2015 and the amendments were advertised allowed on 28 May 2015.

  2. A notice of opposition was filed by Allergan, Inc. (Allergan) on 9 April 2014.  A hearing was held in Canberra on 23 November 2015.  Galderma was represented by Bernadette Hawkins of Cullens.  Allergan was represented by Christian Dimitriadis SC and Gavin Recchia of Davies Collison Cave. 

  3. It is noted that the request for examination in relation to the application was filed on 23 November 2011.  Consequently, substantive amendments of the Patents Act 1990 brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 do not apply to the present application. This includes the amendment to subsection 60 (3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition exists. It is further noted that any subsequent references to sections of the Patents Act relate to the Patents Act 1990 prior to amendment by the Raising the Bar Act.  A similar qualification applies to references to the Patents Regulations 1991.

    Grounds of opposition

  4. The original statement of grounds and particulars was filed on 9 July 2014.  A request to amend the statement was filed on 9 November 2015 and…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Allergan, Inc. v Galderma Research & Development and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] APO 87
Decision Date

CaseChat Overview and Summary

The matter before the Australian Patent Office was an opposition by Allergan, Inc. against the grant of an Australian patent to Galderma Research & Development. The invention related to an injectable composition comprising hyaluronic acid, an a-adrenergic receptor agonist and lidocaine, which is used to prevent or treat skin defects or diminish, decrease or avoid skin reactions due to injection. The opposition was heard on 23 November 2015 and the decision was given by Dr M-A. Fam on 15 December 2015. Allergan's grounds of opposition were novelty, inventive step, manner of manufacture, utility, fair basis and clarity. The opposition was dismissed and the application directed to grant, subject to appeal. Costs were awarded against Allergan. The primary issue for the delegate was whether Galderma's claims lacked novelty, inventive step, manner of manufacture, utility, fair basis and clarity. The delegate found that the claims were novel and inventive in light of the prior art, met the manner of manufacture requirement, were useful, fairly based and clear. The evidence did not establish that the claimed invention would have been obvious to try, or that it lacked inventive step or utility. The claims were construed in light of the specification and the skilled addressee's knowledge and understanding. The delegate's decision was based on a careful analysis of the prior art, the claims and the evidence presented by the parties.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established